{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:44:03Z","timestamp":1768437843490,"version":"3.49.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T00:00:00Z","timestamp":1668902400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The preferred therapeutic regimen for Toxoplasma encephalitis (TE) is a combination of pyrimethamine and sulfadiazine, and trimethoprim-sulfamethoxazole (TMP-SMX) plus azithromycin is the widespread alternative therapeutic regimen. The synergistic sulfonamides tablet contains TMP, sulfadiazine, and SMX and hypothetically could be used for TE treatment. This study aimed to compare the efficacy and safety of synergistic sulfonamides plus clindamycin (regimen B) with TMP-SMX plus azithromycin (regimen A) for the treatment of human immunodeficiency virus (HIV) associated TE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This was an open-labeled, multi-center randomized controlled trial recruited from 11 centers. Each recruited patient was randomly assigned to receive regimen A or regimen B for at least 6 weeks. The overall response was evaluated by assessment of the clinical response of TE-associated clinical features and the radiological response of TE-associated radiological findings. The overall response rate, clinical response rate, radiological response rate, and adverse events were assessed at 2, 6, and 12 weeks. Death events were compared between the two regimens at 6, 12, and 24 weeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 91 acquired immunodeficiency syndrome (AIDS)\/TE patients were included in the final analysis (44 in regimen A <jats:italic toggle=\"yes\">vs<\/jats:italic>. 47 in regimen B). The overall response rate, which refers to the combined clinical and radiological response, was 18.2% (8\/44) for regimen A and 21.3% (10\/47) for regimen B at week 6. The results of clinical response showed that, in comparison with regimen A, regimen B may perform better with regards to its effect on the relief of clinical manifestations (50.0% [22\/44] <jats:italic toggle=\"yes\">vs<\/jats:italic>. 70.2% [33\/47], <jats:italic toggle=\"yes\">P =<\/jats:italic> 0.049). However, no significant differences in radiological response, mortality events, and adverse events were found between the two regimens at week 6.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Synergistic sulfonamides plus clindamycin, as a novel treatment regimen, showed no significantly different efficacy and comparable safety in comparison with the TMP-SMX plus azithromycin regimen. In addition, the regimen containing synergistic sulfonamides may exhibit advantages in terms of clinical symptom alleviation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial Registration:<\/jats:title>\n            <jats:p>ChiCTR.org.cn, ChiCTR1900021195.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002498","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T17:02:58Z","timestamp":1672160578000},"page":"2718-2724","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Synergistic sulfonamides plus clindamycin as an alternative therapeutic regimen for HIV-associated Toxoplasma encephalitis: a randomized controlled trial"],"prefix":"10.1097","volume":"135","author":[{"given":"Yao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing 400036, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanming","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing 400036, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiu","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing 400036, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejiao","family":"He","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing 400036, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing 400036, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing 400036, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqun","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering, Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering, Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing 400036, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,11,20]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/B978-0-444-63849-6.00009-8","article-title":"Central nervous system infection with Toxoplasma gondii","volume":"152","author":"Marra","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S2352-3018(17)30005-X","article-title":"Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2017","journal-title":"Lancet HIV"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1756-0500-6-146","article-title":"Toxoplasma encephalitis in HIV\/AIDS patients admitted to the Douala general hospital between 2004 and 2009: a cross sectional study","volume":"6","author":"Luma","year":"2013","journal-title":"BMC Res Notes"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/CMR.00001-10","article-title":"Importance of nonenteric protozoan infections in immunocompromised people","volume":"23","author":"Barratt","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/hiv.12600","article-title":"Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0","volume":"19","author":"Ryom","year":"2018","journal-title":"HIV Med"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2011.00944_1.x","article-title":"British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals","volume":"12","author":"Nelson","year":"2011","journal-title":"HIV Med"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/clinids\/22.2.268","article-title":"Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS","volume":"22","author":"Katlama","year":"1996","journal-title":"Clin Infect Dis"},{"key":"R9-20250603","first-page":"65","article-title":"Chinese Medical Association Infectious Diseases Society AIDS & Hepatitis C Group and Chinese Center for Disease Control and Prevention. 2019. Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2018) (in Chinese)","volume":"4","year":"2018","journal-title":"Electron J Emerg Infect Dis"},{"key":"R10-20250603","first-page":"419","article-title":"An investigation on antibiotic prescriptions in Peking University School Hospital from 1997 to1999 (in Chinese)","volume":"14","author":"Zhang","year":"2000","journal-title":"Chin J Sch Doct"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"e20146","DOI":"10.1097\/MD.0000000000020146","article-title":"A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections","volume":"99","author":"Li","year":"2020","journal-title":"Medicine"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1086\/339551","article-title":"Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237\/ANRS 039 Study","volume":"34","author":"Chirgwin","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/hiv.12402","article-title":"A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option?","volume":"18","author":"Hernandez","year":"2017","journal-title":"HIV Med"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"e0138204","DOI":"10.1371\/journal.pone.0138204","article-title":"A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans","volume":"10","author":"Wei","year":"2015","journal-title":"PLoS One"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1128\/AAC.42.6.1346","article-title":"Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group","volume":"42","author":"Torre","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-20250603","first-page":"11","article-title":"Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients","volume":"7","author":"Kongsaengdao","year":"2008","journal-title":"J Int Assoc Phys AIDS Care"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:11:00Z","timestamp":1748977860000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,20]]},"references-count":15,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002498","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,20]]}}}